| Similar Articles |
|---|
 |
The Motley Fool
December 28, 2007
Brian Lawler |
Investors Wary on Noven Approval Noven Pharmaceuticals announces that the FDA has issued a tentative approval for one of its drugs, yet shares are trading lower since the news. Is the "tentative" status making investors jittery?   |
The Motley Fool
July 12, 2007
Brian Lawler |
Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
Nursing
May 2012
Tim Blake |
Three Medication Pathways for Bipolar Disorder No matter where you work, you're likely to care for patients with bipolar disorder, which affects about 2.6% of people age 18 and older per year. |
The Motley Fool
August 21, 2008
Rich Smith |
JDS Uniphase Falls off a Cliff JDS Uniphase shares plunge after earnings, hurt by a sizeable earnings miss and guidance that didn't quite meet expectations. |
The Motley Fool
November 9, 2006
Brian Lawler |
Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven. |
The Motley Fool
November 8, 2005
Rich Smith |
Foolish Forecast: Pocket Change at JDS Uniphase Tomorrow, analysts expect the company to report a penny-a-share loss. Looking farther out, they long to see JDS earn a penny of profit before fiscal 2007 begins. |
The Motley Fool
May 2, 2005
Dan Bloom |
More Struggles for JDS Uniphase Tight competition and declining prices hurt third-quarter earnings at the fiber optic components manufacturer. JDS plans to cut jobs and exit some low-margin businesses. |
The Motley Fool
August 19, 2008
Rich Smith |
Foolish Forecast: JDS Uniphase Still Looks Cheap All year long, JDS Uniphase has trounced every earnings estimate Wall Street could hurl its way. Will its fourth quarter be the same? |
The Motley Fool
May 24, 2005
Rich Smith |
JDS Uniphase Buys Something Will Acterna help the telecom play grow, or sink it? It's a pricey acquisition, even at a cost that's just over half the price-to-sales ratio JDS shares currently fetch. |
The Motley Fool
August 20, 2007
Rich Smith |
Foolish Forecast: JDS Uniphase Sees the Light The telecom equipment maker is set to report its fiscal fourth-quarter numbers. Investors, here is what you can expect to see. |
The Motley Fool
May 16, 2008
Rich Smith |
JDS Uniphas-ing Out Stock JDS Uniphase is the latest big name in tech to announce a stock repurchase program. |
The Motley Fool
September 7, 2005
Rich Smith |
JDS Makes a Withdrawal The fiber-optic technology specialist shells out for a new acquisition. How will it affect the balance sheet down the road? And will Wall Street be as forgiving the next time around? |
CRM
September 1, 2009
Christopher Musico |
The 2009 Rising Stars - Lithium Technologies Trusting the community. |
American Family Physician
September 15, 2000 |
Bipolar Disorder Bipolar disorder is an illness that causes extreme mood swings. This condition is also called manic-depressive illness... What are some of the signs of bipolar disorder?... How is bipolar disorder treated?... What can I do to help myself get better?... |
The Motley Fool
December 5, 2005
W.D. Crotty |
Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings. |
The Motley Fool
July 30, 2010
Jeremy Phillips |
Technically, JDS Uniphase Is a Buy The signal line crossover says you should buy JDS Uniphase right now. But you might not want to listen. |
The Motley Fool
September 27, 2011
Dan Caplinger |
Has JDS Uniphase Become the Perfect Stock? Finding companies that have all the right stuff can produce winners. |
AskMen.com
Julian Marcus |
Are You Bipolar? Bipolar disorder, also known as manic-depressive illness, is one of the least understood and potentially most destructive mental health disorders. |
The Motley Fool
September 5, 2007
Brian Lawler |
Not Your Typical Product Recall Shire and Noven will fix an annoying foible of their ADHD patch, Daytrana, making the back adhesive easier to unpeel. |
The Motley Fool
October 8, 2010
Jeremy Phillips |
Time to Sell JDS Uniphase? Let's explore what other investors think about JDS Uniphase. |
The Motley Fool
December 22, 2011
Brian Stoffel |
JDS Uniphase: A Stock Slipping on Hard Times in 2011 An investment in JDS Uniphase is an investment in the communications industry. |
The Motley Fool
November 5, 2010
Anders Bylund |
Finisar and Friends Draw Comfort from JDS Uniphase's Strength The reports of optical networking's death have been greatly exaggerated. |
The Motley Fool
May 1, 2007
Brian Lawler |
Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up. |
The Motley Fool
August 23, 2007
Rich Smith |
JDS Uniphase Sees the Light Shares of the telecom equipment maker are leading Wall Street lower today in the wake of an earnings report featuring better-than-promised sales growth. |
ifeminists
May 10, 2006
Tony Zizza |
Is It Time To Boycott Parade Magazine? Once again Parade magazine is helping pharmaceutical companies sell depression and its drugs. If we are to take AstraZeneca seriously, and bipolar disorder seriously, then we must completely reject the idea of free will, personal responsibility, and good/bad consequences. |
InternetNews
September 1, 2005
Paul Shread |
Ciena, JDS Post Losses Ciena and JDS Uniphase showed Thursday that it's still hard to make money in the telecom equipment market... The broader market was mixed Thursday... The Nasdaq slipped 4 to 2147 and the S&P added 1 to 1221... etc. |
Salon.com
October 4, 2000
Kuhn & Wilson |
The zitty face of depression Drugs for depression and drugs for acne don't always mix well... |
American Family Physician
September 15, 2000
Kim S. Griswold, M.D., M.P.H. & Linda F. Pessar, M.D. |
Management of Bipolar Disorder A comprehensive management program, including collaboration between the patient's family physician and psychiatrist, should be implemented to optimize medical care... |
The Motley Fool
January 9, 2004
Jeff Hwang |
RIM Cashes In Share offering may indicate richly valued shares, but also a quest for long-term value. |
The Motley Fool
April 29, 2004
Bill Mann |
More Pain at JDS Uniphase Anyone who thinks that a capital spending upsurge in telecommunications or data is nigh may want to look at JDS Uniphase's quarterly results and consider them to be a sharp refutation of the notion. |
InternetNews
July 12, 2004
Jim Wagner |
Sun Rising on JDS Java Desktop System devotees attempt to resuscitate interest in the Linux-based desktop system. |
